Anti-Trypanosoma cruzi Cross-Reactive Antibodies Detected at High Rate in Non-Exposed Individuals Living in Non-Endemic Regions: Seroprevalence and Association to Other Viral Serologies

Imagem de Miniatura
Arquivos
art_SABINO_Anti_Trypanosoma_cruzi_Cross_Reactive_Antibodies_Detected_at_2013.PDF (391.38 KB)
Citações na Scopus
8
Tipo de produção
article
Data de publicação
2013
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
SABA, Esber S.
GUEYFFIER, Lucie
DICHTEL-DANJOY, Marie-Laure
POZZETTO, Bruno
BOURLET, Thomas
GUEYFFIER, Francois
MEKKI, Yahia
POTTEL, Hans
VANHEMS, Philippe
Citação
PLOS ONE, v.8, n.9, article ID e74493, 7p, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Cross-reactive antibodies are characterized by their recognition of antigens that are different from the trigger immunogen. This happens when the similarity between two different antigenic determinants becomes adequate enough to enable a specific binding with such cross-reactive antibodies. In the present manuscript, we report the presence, at an ""abnormal"" high frequency, of antibodies in blood samples from French human subjects cross-reacting with a synthetic-peptide antigen derived from a Trypanosoma cruzi (T. cruzi) protein sequence. As the vector of T. cruzi is virtually confined to South America, the parasite is unlikely to be the trigger immunogen of the cross-reactive antibodies detected in France. At present, the cross-reactive antibodies are measured by using an in-house ELISA method that employs the T. cruzi -peptide antigen. However, to underline their cross-reactive characteristics, we called these antibodies ""Trypanosoma cruzi Cross Reactive Antibodies"" or TcCRA. To validate their cross-reactive nature, these antibodies were affinity-purified from plasma of healthy blood donor and were then shown to specifically react with the T. cruzi parasite by immunofluorescence. Seroprevalence of TcCRA was estimated at 45% in serum samples of French blood donors while the same peptide-antigen reacts with about 96% of T. cruzi -infected Brazilian individuals. In addition, we compared the serology of TcCRA to other serologies such as HSV 1/2, EBV, HHV-6, CMV, VZV, adenovirus, parvovirus B19, mumps virus, rubella virus, respiratory syncytial virus, measles and enterovirus. No association was identified to any of the tested viruses. Furthermore, we tested sera from different age groups for TcCRA and found a progressive acquisition starting from early childhood. Our findings show a large seroprevalence of cross-reactive antibodies to a well-defined T. cruzi antigen and suggest they are induced by a widely spread immunogen, acquired from childhood. The etiology of TcCRA and their clinical relevance still need to be investigated.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/4084
Referências
  1. Arbuckle MR, 2003, NEW ENGL J MED, V349, P1526, DOI 10.1056/NEJMoa021933
  2. Ayub MJ, 2009, BIOCHEM BIOPH RES CO, V382, P30, DOI 10.1016/j.bbrc.2009.02.095
  3. Benvenuti LA, 2008, ANN TROP MED PARASIT, V102, P481, DOI 10.1179/136485908X311740
  4. Caballero ZC, 2007, CLIN VACCINE IMMUNOL, V14, P1045, DOI 10.1128/CVI.00127-07
  5. Cooley G, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000316
  6. Cusick MF, 2012, CLIN REV ALLERG IMMU, V42, P102, DOI [10.1007/s12016-011-8293-8, 10.1007/s12016-011-8294-7]
  7. Elias FE, 2003, AM J TROP MED HYG, V68, P242
  8. El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631
  9. Ercolini AM, 2009, CLIN EXP IMMUNOL, V155, P1, DOI 10.1111/j.1365-2249.2008.03834.x
  10. Flores-Chavez M, 2012, CLIN VACCINE IMMUNOL, V19, P1353, DOI 10.1128/CVI.00227-12
  11. Giordanengo L, 2002, EUR J IMMUNOL, V32, P1003, DOI 10.1002/1521-4141(200204)32:4<1003::AID-IMMU1003>3.3.CO;2-G
  12. Giordanengo L, 2001, CLIN EXP IMMUNOL, V124, P266, DOI 10.1046/j.1365-2249.2001.01512.x
  13. HOFT DF, 1989, INFECT IMMUN, V57, P1959
  14. Islam Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043976
  15. Levin MJ, 2008, AUTOIMMUNITY, V41, P429, DOI 10.1080/08916930802031702
  16. Marin JA, 2007, CIRCULATION, V115, P1109, DOI 10.1161/CIRCULATIONAHA.106.624296
  17. Oelemann WMR, 1999, TRANSFUSION, V39, P711, DOI 10.1046/j.1537-2995.1999.39070711.x
  18. Pais FS, 2008, MICROBES INFECT, V10, P716, DOI 10.1016/j.micinf.2008.03.005
  19. Palomino SAP, 2000, ANN TROP MED PARASIT, V94, P571
  20. Rashid T, 2012, AUTOIMMUNE DIS
  21. Ribeiro CH, 2009, MOL IMMUNOL, V46, P1092, DOI 10.1016/j.molimm.2008.10.034
  22. Sabino EC, 2013, CIRCULATION, V127, P1105, DOI 10.1161/CIRCULATIONAHA.112.123612
  23. Talvani A, 2006, MICROBES INFECT, V8, P2459, DOI 10.1016/j.micinf.2006.06.006
  24. Teixeira ARL, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001000
  25. Teixeira ARL, 2011, CLIN MICROBIOL REV, V24, P592, DOI 10.1128/CMR.00063-10
  26. The UniProt Consortium, 2011, NUCLEIC ACIDS RES, V40, pD71, DOI 10.1093/NAR/GKR981]
  27. Tischer BK, 2010, VET MICROBIOL, V140, P266, DOI 10.1016/j.vetmic.2009.06.020
  28. VANVOORHIS WC, 1993, J EXP MED, V178, P681, DOI 10.1084/jem.178.2.681
  29. Wedemeyer H, 2001, J VIROL, V75, P11392, DOI 10.1128/JVI.75.23.11392-11400.2001

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - LIM/46
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03